A drug safety evaluation of valsartan

Bibliography

• Cohen JS. Adverse drug effects, compliance and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference. Arch Intern Med 2001;161:880-5
   PubMed Web of Science ®Google Scholar
• Elliot WJ, Plauschinat CA, Skrepnek GH, Persistence, adherence and risk of discontinuation associated with commonly prescribed antihypertensive monotherapies. J Am Board Fam Med 2007;20:72-80
   PubMed Web of Science ®Google Scholar
• Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy:a review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42
   PubMed Web of Science ®Google Scholar
• Moreaux B, Advenier C, Gustin P. Role of bradykinin and tachykinins in the potentiation by enalapril of coughing induced by citric acid in pigs. Fundam Clin Pharmacol 2001;15:23-9
   PubMed Web of Science ®Google Scholar
• Oparil S, Dyke S, Harris F, The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810
   PubMed Web of Science ®Google Scholar
• Black HR, Bailey J, Zappe D, Samuel R. Valsartan. More than a decade of experience. Drugs 2009;69:2393-414
   PubMed Web of Science ®Google Scholar
• Cohn J, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Mc Murray JJ, Velazquez EJ, Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 2003;349:1893-906
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomized trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Locatelli F, Palmer BF, Nashihara N, Ecder T. Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan. Curr Med Res Opin 2009;25:2933-49
   PubMed Web of Science ®Google Scholar
• Diovan (valsartan) tablets prescribing information. East Hannover (NJ): Novartis Pharmaceutical Corporation, 2008 Dec (online). Available from URL: htpp://www.pharma.us.novartis.com/products/name/diovan.jsp
   Google Scholar
• Kumbasar B, Atlibatur Akbas F, Serez K, High-dose exposure to valsartan with suicidal intention. Int J Clin Pharmacol Ther 2004;42:328-9
   PubMed Web of Science ®Google Scholar
• Biswas PN, Wilton LV, Shakir SW. The safety of valsartan:results of a pstmarketing surveillance study on 12881 patients in England. J Hum Hypertens 2002;16:795-803
   PubMed Web of Science ®Google Scholar
• Holwerda NJ, Fogari R, Angeli P, Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension:efficacy and safety compared with placebo and enalalpril. J Hypertens 1996;14:1147-51
   PubMed Web of Science ®Google Scholar
• Botero R, Matiz H, Maria E, Efficacy and safety of valsartan compared with enalapril at different altitudes. Int J Cardiol 2000;72:247-54
   PubMed Web of Science ®Google Scholar
• Black HR, Graff A, Shute D, Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension:efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9
   PubMed Web of Science ®Google Scholar
• Benz J, Oshrain C, Henry D, Valsartan, a new angiotensin II receptor antagonist:a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997;37:101-7
   PubMed Web of Science ®Google Scholar
• Corea L, Cardoni O, Fogari R, Valsartan, a new angiotensin II antagonist for the treatment of essential hypertesion:a comparative study of the efficacy and safety against amlodipine. Clin Pharmaol Ther 1996;60:341-6
   PubMed Web of Science ®Google Scholar
• Malacco E, Vari N, Capuano V, A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients:the Val-Syst study. Clin Ther 2003;25:2765-80
   PubMed Web of Science ®Google Scholar
• Hegner G, Faust G, Frytag F, Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension:efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol 1997;52:173-7
   PubMed Web of Science ®Google Scholar
• Zappe DH, Sowers JR, Hsueh WA, Metabolic and antihypertensive effects of combined antagonist receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens 2008;10:894-903
   PubMed Web of Science ®Google Scholar
• Pool J, Glazer R, Weinberger M, Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy:a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29:61-73
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, TyKarski A, Baumgart P, Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. Blood Press 2008;17(Suppl 1):15-23
   Web of Science ®Google Scholar
• White WB, Calhoun DA, Samuel R, Improving blood pressure control:increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan/hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens 2008;10:450-8
   PubMed Web of Science ®Google Scholar
• Philipp T, Smith TR, Glazer R, Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80
   PubMed Web of Science ®Google Scholar
• Braun N, Ulmer HJ, Ansari A, Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Curr Med Res Opin 2009;25:421-30
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Derosa G, Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-4
   PubMed Web of Science ®Google Scholar
• Fogari R, Malamani GD, Corradi L, Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. Adv Ther 2010;27:48-55
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Mugellini A, Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr 2009;48:401-5
   PubMed Web of Science ®Google Scholar
• Flynn JT, Meyers KE, Neto JP, Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension 2008;52:222-8
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Zoppi A, Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004;59:863-8
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Poletti L, Sexual activity in hypertensive men treated with valsartan or carvedilol: a cross-over study. Am J Hypertens 2001;14:27-31
   PubMed Web of Science ®Google Scholar
• Fogari R, Preti P, Derosa G, Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002;58:177-80
   PubMed Web of Science ®Google Scholar
• Jugdutt BJ. Valsartan in the treatment of heart attack survivors. Vasc Health Risk Manag 2006;2:125-38
   PubMedGoogle Scholar
• Sugihara M, Miura S, Takamiya Y. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009;32:625-30
   PubMed Web of Science ®Google Scholar
• Hollenberg NK, Parving HH, Viberti G, Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921-6
   PubMed Web of Science ®Google Scholar
• NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-90
   PubMed Web of Science ®Google Scholar
• Fogari R, Derosa G, Rinaldi A, Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 2005;28:209-14
   PubMed Web of Science ®Google Scholar
• Fogari R, Preti P, Zoppi A, Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. Inter Med 2008;47:1851-7
   PubMed Web of Science ®Google Scholar
• Bakris GL, Siomos E, Richardson D, ACE inhibition or angiotensin receptor blockade:impact on potassium in renal failure.VAL-K Study Group. Kidney Int 2000;58:2084-92
   PubMed Web of Science ®Google Scholar
• Durmus A, Dogan E, Erkoc R, Effect of valsartan on erythropoietoin and hemoglobin levels in stage II-IV chronic kidney disease patients. Int J Clin Pract 2005;59:1001-4
   PubMed Web of Science ®Google Scholar
• Leidig M, Bambauer L, Kirchertz EJ, Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol 2008;69:425-32
   PubMed Web of Science ®Google Scholar
• Andres A, Morales E, Morales JM. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation:a randomized multicenter study. Transplant Proc 2006;38:2419-23
   PubMed Web of Science ®Google Scholar
• Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 8th edition, Lippincott Williams & Wilkins, Wolters Kluwer; 2008
   Google Scholar
• Sipahi I, Debanne S, Rowland DY, Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncol 2010;11:627-36
   PubMed Web of Science ®Google Scholar
• Clere N, Corre I, Faure S, Deficiency or blockade of angiotensin II type 2 receptor Delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer 2010;127:2279-91
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber MA. Angiotensin-receptor blockade, cancer and concerns. Lancet Oncol 2010;11:820-1
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhao W, Wu G. Valsartan inhibits NPC cell line CNE-2 proliferation and invasion and promotes its sensitivity to radiation. Eur J Cancer Prev 2009. [Epub ahead of print]
   Google Scholar
• Wang L, Cai SR, Zhang CH, Effects of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers on limphangiogenesis of gastric cancer in a nude mouse model. Chin Med J 2008;121:2167-71
   PubMed Web of Science ®Google Scholar